Prospect News: News for Array BioPharma Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with A > All stories on Array BioPharma Inc.

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Array BioPharma Inc.

7/30/2019	CVLM	Array BioPharma holders may convert, put 2.625% notes due to merger
2/6/2018	CV	Market Commentary: Convertibles trading volume light amid equity market volatility; Array, Lumentum gain
2/6/2018	CV	Market Commentary: Morning Commentary: Convertibles trading volume light amid equity market volatility
12/22/2017	CV	Market Commentary: Cobalt trading frenzy goes on; Array jumps up; WWE smacked down; EZCorp strengthens
12/4/2017	CVLM	Array calls last $6.2 million 3% convertibles due 2020 for redemption
11/22/2017	CV	Market Commentary: High trade volume for Intel continues; Everbridge, Square, Array make gains
11/21/2017	CV	Market Commentary: Palo Alto jumps on earnings report, Array BioPharma’s new notes gain steam, Tesla active
11/20/2017	CVLM	Array BioPharma avoids equity dilution with upsized exchange agreement
11/20/2017	CVLM	Array to swap $19 million more 2020 convertibles for stock, new notes
11/20/2017	CV	Market Commentary: Intel continues to dominate trading, Array BioPharma upsizes exchange agreement
11/16/2017	CVLM	Array to swap $107 million of 2020 convertibles for stock, new notes
9/27/2016	CV	Market Commentary: Array BioPharma surges again in active trade; Great Plains, Goldman Sachs BDC launch deals
9/27/2016	CV	Market Commentary: Morning Commentary: Array BioPharma surges again in active trade; Priceline bonds slip
9/2/2016	PP	Array BioPharma raises $10 million from placement of 5% convertibles
8/22/2016	PP	Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
8/22/2016	CV	Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
5/31/2016	PP	Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
5/31/2016	CV	Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
5/31/2016	CV	Market Commentary: Morning Commentary: Health care in focus as sector lifts following Celator acquisition news
11/4/2015	PP	Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
11/4/2015	CV	Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
11/4/2015	CV	Market Commentary: Morning Commentary: Convertibles primary remains quiet; Tesla Motors adds after earnings miss
1/26/2015	PP	Market Commentary: FXCM strengthens; Molycorp adds; Array up; convertibles mostly quiet ahead of Nor’easter
1/26/2015	CV	Market Commentary: FXCM strengthens; Molycorp adds; Array up; convertibles mostly quiet ahead of Nor’easter
1/23/2015	PP	Market Commentary: Priceline active; FXCM better despite lower shares; Array BioPharma surges on drug deal
1/23/2015	CV	Market Commentary: Priceline active; FXCM better despite lower shares; Array BioPharma surges on drug deal
6/7/2013	CV	Array BioPharma greenshoe ups 3% convertibles deal to $132.25 million
6/6/2013	CV	Market Commentary: Planned Jarden looks fair to rich; existing Jarden slips on swap; market seen quiet, weak
6/5/2013	CV	Market Commentary: Array adds a point in busy debut; market weaker; DDR off 0.25 point; Prologis in 0.5 point
6/5/2013	CV	New Issue: Array BioPharma sells upsized $115 million seven-year convertibles at 3%, up 32.5%
6/4/2013	CV	Market Commentary: New Dominions trade around reoffered price and lower; planned Array note valuations eyed
6/3/2013	CV	Array BioPharma to sell $100 million seven-year convertibles to yield 3%-3.5%, up 27.5%-32.5%
6/3/2013	CV	Market Commentary: Dominion seen in gray near reoffer price; convertibles mostly quiet, better sellers seen
12/21/2012	HYPF	Array BioPharma files $200 million shelf for stock, debt, preferreds
11/9/2012	PP	Array BioPharma prices $65.7 million public sale of its stock at $3.65
11/8/2012	PP	Array BioPharma aims to price public sale of its stock with greenshoe
2/14/2012	PP	Array BioPharma wraps $59.8 million public offering of common stock
2/8/2012	PP	Array BioPharma to price public offering of stock with greenshoe
11/23/2011	CVHYPF	Array BioPharma files $150 million shelf for stock and preferreds
5/3/2011	PP	Array BioPharm heralds $30 million convertible preferreds placement
5/2/2011	PP	Array BioPharma to pay down loan facility with preferreds issuance
9/21/2009	SS	Array Biopharma shareholder Kopp Investment reports 6.2% stake
8/3/2009	SS	Array Biopharma shareholder Kopp Investment reports 5.2% stake
5/19/2009	PP	New Issue: Array Biopharma concludes $40 million loan accompanied by warrants with Deerfield
11/7/2008	CVHY	Array Biopharma files $150 million shelf registration
5/5/2008	PP	New Issue: Array Biopharma orchestrates $80 million loan with Deerfield
11/6/2006	BT	Array ups R&D spending by $2.2 million for first quarter of fiscal 2007
10/6/2006	BTCV	Array Biopharma files $150 million stock, warrant shelf
9/14/2006	BT	Array BioPharma gets $3 million milestone from AstraZeneca
6/27/2006	BT	Array says it will enter new research partnership by end of year
6/22/2006	BT	Array BioPharma gains from $32 million real estate transaction
6/8/2006	BT	AstraZeneca, Array begin phase 2 studies of melanoma treatment
4/26/2006	BT	Array BioPharma begins phase 1 trial of MEK inhibitor for inflammatory disease
4/17/2006	BT	Array BioPharma achieves research milestone in Genentech collaboration
4/10/2006	BT	Array BioPharma to receive $1 million milestone payment from AstraZeneca
1/24/2006	BT	Array BioPharma gets $1 million milestone payment from AstraZeneca for MEK work
1/17/2006	BT	Array BioPharma begins phase 1 trial for cancer drug ARRY-334543
10/13/2005	BT	Array BioPharma, Genentech expand oncology collaboration
7/5/2005	BT	Array BioPharma obtains $10 million term loan, $5 million equipment advances, $2 million revolver

©2026 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.